Cardiac Amyloidosis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Cardiac Amyloidosis Overview

Cardiac amyloidosis is a heart condition where misshapen proteins get stuck in and around different parts of the heart. As these proteins build up, the heart struggles to pump blood so it tries to pump harder. Ultimately, the extra effort weakens and damages the heart, causing it to fail.

“Cardiac Amyloidosis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cardiac Amyloidosis Market.

The Cardiac Amyloidosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Cardiac Amyloidosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Cardiac Amyloidosis treatment therapies with a considerable amount of success over the years. Cardiac Amyloidosis Key players such as – BSIM Therapeutics, Neurimmune AG, Intellia Therapeutics, Alexion Pharmaceuticals, Ionis Pharmaceuticals, and others, are developing therapies for the Cardiac Amyloidosis treatment 

• Cardiac Amyloidosis Emerging therapies such as – BSIM-3A05D, NI006, NTLA-2001, ALXN 2060, Eplontersen, and others are expected to have a significant impact on the Cardiac Amyloidosis market in the coming years.   
• On January 24, 2022, Ionis Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) had granted orphan drug designation to eplontersen, an investigational antisense medicine for the treatment of people living with transthyretin-mediated amyloidosis.
• In January 2022, Neurimmune AG announced that it had entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, to develop NI006, an investigational human monoclonal antibody specifically targeting misfolded transthyretin
• In March 2020, Ionis Pharmaceuticals initiated a Phase III global, double blind, randomized, placebo-controlled study to evaluate the efficacy and safety of ION-682884 in patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Route of Administration

Cardiac Amyloidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Cardiac Amyloidosis Pipeline Therapeutics Assessment

• Cardiac Amyloidosis Assessment by Product Type
• Cardiac Amyloidosis By Stage and Product Type
• Cardiac Amyloidosis Assessment by Route of Administration
• Cardiac Amyloidosis By Stage and Route of Administration
• Cardiac Amyloidosis Assessment by Molecule Type
• Cardiac Amyloidosis by Stage and Molecule Type

DelveInsight’s Cardiac Amyloidosis Report covers around 20+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Cardiac Amyloidosis Therapeutics Market include:

Key companies developing therapies for Cardiac Amyloidosis are – Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Eidos Therapeutics, Pfizer Inc., GlaxoSmithKline, Prothena Biosciences Inc., Akcea Therapeutics, Janssen Pharmaceuticals, Takeda Pharmaceutical Company, Caelum Biosciences, and others.

Emerging Cardiac Amyloidosis Drugs Under Different Phases of Clinical Development Include:

• BSIM-3A05D: BSIM Therapeutics
• NI006: Neurimmune AG
• Acoramidis: Eidos Therapeutics
• NTLA-2001: Intellia Therapeutics
• ALXN 2060: Alexion Pharmaceuticals
• Eplontersen: Ionis Pharmaceuticals

Get a Free Sample PDF Report to know more about Cardiac Amyloidosis Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/sample-request/cardiac-amyloidosis-pipeline-insight

Cardiac Amyloidosis Pipeline Analysis:

The Cardiac Amyloidosis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Cardiac Amyloidosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cardiac Amyloidosis Treatment.
• Cardiac Amyloidosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cardiac Amyloidosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cardiac Amyloidosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Cardiac Amyloidosis product details are provided in the report. Download the Cardiac Amyloidosis pipeline report to learn more about the emerging Cardiac Amyloidosis therapies

Cardiac Amyloidosis Pipeline Market Drivers

• Improving Healthcare Infrastructure
• Demand for New and Effective Cardiac Amyloidosis Drugs

Cardiac Amyloidosis Pipeline Market Barriers

• High cost of Cardiac Amyloidosis treatment
• Lack of awareness regarding the cardiac amyloidosis in developing countries

Scope of Cardiac Amyloidosis Pipeline Drug Insight    

• Coverage: Global
• Key Cardiac Amyloidosis Companies: BSIM Therapeutics, Neurimmune AG, Intellia Therapeutics, Alexion Pharmaceuticals, Ionis Pharmaceuticals, and others
• Key Cardiac Amyloidosis Therapies: BSIM-3A05D, NI006, NTLA-2001, ALXN 2060, Eplontersen, and others
• Cardiac Amyloidosis Therapeutic Assessment: Cardiac Amyloidosis current marketed and Cardiac Amyloidosis emerging therapies
• Cardiac Amyloidosis Market Dynamics: Cardiac Amyloidosis market drivers and Cardiac Amyloidosis market barriers 

Request for Sample PDF Report for Cardiac Amyloidosis Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Cardiac Amyloidosis drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting